IRVINE, Calif., Nov. 5, 2014 /PRNewswire/ -- According to the results of a national survey conducted by Wakefield Research on behalf of Allergan, Inc., nearly 60% of women surveyed, ages 21-65 (n=500) say they'd rather have a more youthful looking face than a more youthful looking body1. Of the respondents, 64% noted that the shape of their face has changed as they have aged, and 44% have noticed a decrease in cheek volume or fullness in the past 10 years. Of women surveyed, 44% believe that if they lose volume in their cheek area, there is nothing they can do to correct it.1
"My patients often come to see me about a variety of concerns, including sunken, hollowed out cheeks.2,3 What they may not realize is that the problem is caused by age-related volume loss," says Dr. Heidi Waldorf, a Board Certified Dermatologist at Mount Sinai Medical Center in New York City. "The good news is there is a non-surgical treatment option, called JUVEDERM VOLUMA® XC, that temporarily corrects volume loss in the midface (or cheek area). It provides a natural looking lift and contour to the cheeks. It is the only hyaluronic acid filler that is FDA-approved for this area4."
JUVEDERM VOLUMA® XC is a gel that is injected into the cheeks to correct age-related volume loss4. It provides contour and a subtle lift to temporarily restore a more youthful profile to the face.4 The results are natural-looking and last for up to two years with optimal treatment.4,5 JUVEDERM VOLUMA® XC recently received a "2014 Breakthrough Award" as part of Allure Magazine's annual Best of Beauty list.6
Consumers can visit www.Juvederm.com to take a short quiz and find out if they are experiencing age-related volume loss. They can also search for a healthcare professional who will help determine if JUVEDERM VOLUMA® XC is right for them.
Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 11,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics and urologics, Allergan is proud to celebrate more than 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.
JUVEDERM VOLUMA® XC Important Information
JUVEDERM VOLUMA® XC injectable gel is for deep injection in the cheek area to correct age-related volume loss in adults over the age of 21.
IMPORTANT SAFETY INFORMATION
Are there any reasons why I should not receive JUVEDERM VOLUMA® XC? Do not use the product if you have severe allergies with a history of severe allergic reactions (anaphylaxis), or if you are allergic to lidocaine or the proteins (grampositive bacterial proteins) used to make the hyaluronic acid (HA) in JUVEDERM VOLUMA® XC.
What precautions should my healthcare professional advise me about?
- The safety of JUVEDERM VOLUMA® XC injectable gel for use during pregnancy, in women who are breastfeeding, or in patients with very thin skin in the cheek area has not been studied
- The safety for use in patients under 35 years or over 65 years has not been studied
- The safety and effectiveness for treatment in areas other than the cheek area have not been established
- The safety for use in patients with a history of excessive scarring or pigmentation disorders has not been studied and may result in additional scars or changes in pigmentation
- The long-term safety of repeat treatments has not been established
- Patients who experience skin injury near the site of injection may be at a higher risk for side effects
- Tell your healthcare professional if you are on therapy used to decrease the body's immune response (immunosuppressive therapy). Use may result in an increased risk of infection
- Tell your healthcare professional if you are using medications that can prolong bleeding, such as aspirin, ibuprofen, or other blood thinners; as with any injection, this may result in increased bruising or bleeding at the injection site
- Minimize strenuous exercise and exposure to extensive sun or heat within the first 24 hours following treatment
What are possible side effects?
Side effects are moderate (uncomfortable) and generally last 2 to 4 weeks. The most common side effects include temporary reactions at the treatment site such as tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration, and itching.
To report a side effect, please call Allergan Product Surveillance at 1-877-345-5372.
For more information, please see www.juvederm.com or call the Allergan Product Support line at 1-800-766-0171.
JUVEDERM VOLUMA® XC injectable gel is available by prescription only.
This press release contains "forward‐looking statements," including but not limited to, the statements by Dr. Waldorf as well as other statements regarding the safety and efficacy of JUVÉDERM VOLUMA® XC. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include, among other things, general industry and pharmaceutical market conditions; technological advances and patents attained by competitors; inconsistency of treatment results among patients; potential difficulties in manufacturing; challenges related to new product marketing, such as the unpredictability or market acceptance for new products and/or the acceptance of new indications for such products; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward‐looking statements except as required by law. Additional information concerning these and other risks can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Allergan's most recent Annual Report on Form 10‐K and any subsequent Quarterly Reports on Form 10‐Q. Copies of Allergan's press releases and additional information about Allergan are available at www.allergan.com.
1 Wakefield Research Volume Loss Survey 2014
2 Little JW. Volumetric perceptions in midfacial aging with altered priorities for rejuvenation. Plast Reconstr Surg. 2000;105(1):252-266. Little(2000)/p259/A
3 Donofrio LM.Fat distribution: a morphologic study of the aging face. Dermatol Surg. 2000;26 (12):1107-1112. Donofrio(2003)/p2003/p1108/A&B&C
4 JUVEDERM VOLUMA® XC Product Label, 2013
5 Data on file, Allergan, Inc.; JUVEDERM VOLUMA DFU, 2013
6 Allure Magazine, October, 2014
© 2014 Allergan, Inc. Irvine, CA 92612. ®marks owned by Allergan, Inc.
SOURCE Allergan, Inc.